Mainz Biomed N.V. (MYNZ) Performance and Fundamentals Dashboard tells a completely different story

Mainz Biomed N.V. (NASDAQ: MYNZ) stock fell -6.78% on Monday to $3.30 against a previous-day closing price of $3.54. With 0.12 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.11 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $3.4800 whereas the lowest price it dropped to was $3.1100. The 52-week range on MYNZ shows that it touched its highest point at $9.61 and its lowest point at $2.84 during that stretch. It currently has a 1-year price target of $9.00. Beta for the stock currently stands at 0.58.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MYNZ was down-trending over the past week, with a drop of -2.08%, but this was up by 12.63% over a month. Three-month performance dropped to -32.03% while six-month performance fell -50.00%. The stock lost -62.16% in the past year, while it has lost -53.52% so far this year. A look at the trailing 12-month EPS for MYNZ yields -1.95 with Next year EPS estimates of -1.54. For the next quarter, that number is -0.47. This implies an EPS growth rate of -122.60% for this year and 17.60% for next year.

Float and Shares Shorts:

At present, 14.92 million MYNZ shares are outstanding with a float of 12.00 million shares on hand for trading. On Aug 30, 2023, short shares totaled 37780.0, which was 0.24% higher than short shares on Jul 30, 2023. In addition to Mr. Guido Baechler as the firm’s CEO & Director, Mr. William J. Caragol serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 0.17% of MYNZ’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 0.08% of MYNZ, in contrast to 0.04% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in MYNZ with 0.09% of the stake, Greenwich Investment Management, holds 14,159 shares worth 14,159. A second-largest stockholder of MYNZ, Steward Partners Investment Advis, holds 1,500 shares, controlling over 0.01% of the firm’s shares. NewEdge Advisors LLC is the third largest shareholder in MYNZ, holding 1,000 shares or 0.01% stake. With a 0.04% stake in MYNZ, the Fidelity Nasdaq Composite Index F is the largest stakeholder. A total of 6,180 shares are owned by the mutual fund manager.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, MYNZ reported revenue of $139.24k and operating income of -$6.88M. The EBITDA in the recently reported quarter was -$6.83M and diluted EPS was -$0.48.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MYNZ since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With MYNZ analysts setting a high price target of $11.00 and a low target of $7.00, the average target price over the next 12 months is $9.00. Based on these targets, MYNZ could surge 233.33% to reach the target high and rise by 112.12% to reach the target low. Reaching the average price target will result in a growth of 172.73% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.